Publications

5674 Results

N-ras mutations in acute myelogenous leukemia: A review of the current literature and an update of the Southwest Oncology Group experience.

Authors
JP Radich;KJ Kopecky;F Appelbaum;CL Willman;SJ Collins
Journal / Conference
Leukemia and Lymphoma 6:325-334
Year
1992
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8600, SWOG-8750

Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney: A Southwest Oncology Group study.

Authors
SA Taylor;P Goodman;ED Crawford;WJ Stuckey;RL Stephens;ER Gaynor
Journal / Conference
IND 10:55-56
Year
1992
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8728

A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study.

Authors
BL Zidar;B Metch;SP Balcerzak;HI Pierce;L Militello;MD Keppen;JL Berenberg
Journal / Conference
Cancer 70(10):2547-2551
Year
1992
Research Committee(s)
Sarcoma
Study Number(s)
SWOG-8731

A Southwest Oncology Group phase I study of sequential combination of recombinant interferon-y and recombinant interleukin-2 in patients with cancer.

Authors
CW Taylor;EM Chase;JA Neidhart;JJ Rinehart;RP Whitehead;RC Gonzalez;PA Bunn;EM Hersh
Journal / Conference
Journal of Immunotherapy 3:176-183
Year
1992
Research Committee(s)
Developmental Biologics
Study Number(s)
SWOG-8801

Melphalan GM-CSF: A phase I study.

Authors
E Poplin;H Smith;B Behrens;B Redman;L Flaherty;J Neidhart;D Alberts
Journal / Conference
Gyn Onc 44:66-70
Year
1992
Research Committee(s)
Developmental Biologics
Study Number(s)
SWOG-8825

Prognostic significance of S-Phase fraction in good risk node-negative breast cancer patients.

Authors
MC Mathieu;MA Owens;LG Dressler;LE Eudey;DC Tormey;CK Osborne;KW Gilchrist;EG Mansour;MD Abeloff;WL McGuire
Journal / Conference
JCO 10(3):428-432
Year
1992
Research Committee(s)
Breast
Study Number(s)
SWOG-8294 (INT-0011) (EST-1180)

Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia-results of a Southwest Oncology Group study of rubidazone vs adriamycin for remission induction, prophylactic intrathecal therapy, late intensifica- tion, and levamisole maintenance.

Authors
FS Morrison;KJ Kopecky;D Head;JW Athens;SP Balcerzak;C Gumbart;L Dabich;JJ Costanzi;C Coltman, Jr;JH Saiki;KK Hussein;CJ Fabian;FR Appelbaum
Journal / Conference
Leukemia 6(7):708-714
Year
1992
Research Committee(s)
Leukemia
Study Number(s)
SWOG-7823/24/25/26

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study.

Authors
PM Ravdin;S Green;T Melink-Dorr;WL McGuire;C Fabian;RP Pugh;RD Carter;SE Rivkin;JR Borst;RJ Belt;B Metch;CK Osborne
Journal / Conference
JCO 10(8):1284-1291
Year
1992
Research Committee(s)
Breast
Study Number(s)
SWOG-8228

Chemotherapy versus observation in high-risk node-negative breast cancer patients.

Authors
EG Mansour;L Eudey;DC Tormey;AH Shatila;CK Osborne;KW Gilchrist;MR Cooper;G Falkson
Journal / Conference
Journal of the National Cancer Institute Monographs 11:97-104
Year
1992
Research Committee(s)
Breast
Study Number(s)
SWOG-8294 (INT-0011) (EST-1180)

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

Authors
DC Allred;R Molina;AK Tandon;SJ Schnitt;KW Gilchrist;CK Osborne;DC Tormey;WL McGuire
Journal / Conference
Human Pathology 23(9):974-979
Year
1992
Research Committee(s)
Breast
Study Number(s)
SWOG-8696 (INT-0076) (EST-7186)